Worked example — the CV

What Evident produces — in full.

J. Doe has spent eleven years in medical affairs — a PhD scientist, then a medical science liaison, now leading field medical for an oncology portfolio. For eight months the applications have gone to Medical Affairs Director roles, and they have not landed. The CV below is the one built after the aim changed: same eleven years, written for a market-access reader. The tailored one-page CV, three before/after rewrites, the fit verdict, and one example of the no-fabrication gate refusing a line.

Role this CV was tailored for
Associate Director, Market Access
A global pharmaceutical company, Basel — full-time
“You will own the value narrative for an oncology asset across European markets, lead health-technology assessment submissions with local teams, and work with health economics to turn clinical evidence into a payer-facing case.”
Not a role J. Doe was applying to. It came from the career-exploration pass — see how it surfaced →
Tailored CV — one page
J. Doe, PhD
Medical Affairs Lead — Oncology
Basel, Switzerland · j.doe@example.com · Swiss work authorisation
Profile

Medical affairs leader in oncology, eleven years from bench to field leadership. Builds the clinical evidence story that payers and regulators read: two national reimbursement dossiers carried the value narrative I wrote with health economics. Comfortable where the science meets the commercial question — which is the ground this role sits on.

Experience
Field Medical Lead, Oncology — Vantis Pharma
2021 – present
  • Built and ran a 40-clinician advisory network across six European markets; the evidence gaps it surfaced shaped two national reimbursement dossiers.
  • Co-authored the clinical value narrative behind a national health-technology assessment submission — approved without a major objection.
  • Translated Phase III endpoints into the payer value story for three markets, working alongside health economics and outcomes research.
  • Led a 5-person field medical team through a portfolio expansion; cut evidence-request turnaround from 14 days to 6.
Medical Science Liaison, Oncology — Vantis Pharma
2018 – 2021
  • Owned scientific engagement for two tumour types across DACH; briefed the cross-functional launch team on the evidence positions that decided label messaging.
  • Ran the investigator-initiated study pipeline: 11 proposals triaged, 4 funded, 2 published.
Postdoctoral Researcher, Translational Oncology — University Hospital Basel
2015 – 2018
  • Biomarker work in solid tumours; first author on three peer-reviewed papers.
Selected capabilities
Health-technology assessment submissions Payer value narrative HEOR collaboration Cross-market launch Advisory boards Evidence generation strategy
Education
PhD, Molecular Oncology — University of Zurich · MSc, Molecular Biology

Engine summary — this tailoring pass

GOOD FIT
66 → 74 ↑
Worth tailoring. Four of the six things this role asks for are already in the history — they were buried under medical-affairs phrasing a market-access reader does not scan for.
Before / after — 3 rewrites from this pass
Before Responsible for building relationships with key opinion leaders.
After Built and ran a 40-clinician advisory network across six markets – the evidence gaps it surfaced shaped two national reimbursement dossiers.
Same fact, stated at the altitude it happened at. The dossier outcome was in the history and had never reached the page.
Before Supported market access colleagues with scientific input.
After Co-authored the clinical value narrative behind a national health-technology assessment submission – approved without a major objection.
"Supported" is the word that costs a career changer the interview. The contribution was authorship, and the record says so.
Before Involved in health economics discussions for several markets.
After Translated Phase III endpoints into the payer value story for three markets, with health economics and outcomes research.
Names the literal term a market-access recruiter searches for, from work that actually happened. Nothing added.
Gate fired — a line the engine refused to write
“Led pricing negotiations with national payers.”

Nothing in the history evidences owning a negotiation — J. Doe contributed the clinical evidence that negotiators used. The line would have read well to a market-access hiring manager and would not have survived the first question about it. This is the failure mode a career change invites, and the gate exists for exactly it: the CV claims the transferable thing, never the adjacent thing.